Direct benefits | +1 | “This drug may result in tumour shrinkage” | Pearson coefficient based on mean for each form | Benefits possibility: 0.984 |
| | “You may experience relief of your symptoms” | | |
| | “Results in animals are promising” | | |
| | “This may induce an immune response to your cancer” | | |
| | | | |
| 0 | “You may or may not benefit” | | |
| | “Direct benefit can not be guaranteed” | | |
| | “You may not benefit from the procedures” | | Direct benefits proportion: 0.982 |
| | “You are the first person to receive this drug” | | |
| −1 | “You are unlikely to benefit from the drug” | | |
| | “This treatment is not a cure” | | |
| | “Despite treatment, your condition will likely worsen” | | |
| | “Any improvement will stop when study ends” | | |
| | | | |
Other | A | “Your participation may benefit others with the disease” | Cohen’s kappa | 0.981 |
| | “You will be helping scientists to learn whether…” | | |
| | | | |
| P | “The goal of this study is to test the drug’s safety” | | 0.987 |
| | “The study is designed to determine if…” | | |
| | | | |
| H | “The treatment you receive may even be harmful” | | 1.00 |
| | “The approach may prove to be toxic” | | |
| | | | |
Agent | +1 | “drug”, “gene therapy”, “medicine”, “vaccine”, “therapy”, “treatment”, “immunisation” | Pearson coefficient based on mean for each form | 0.987 |
| 0 | “approach”, “gene transfer”, “injection”, “method”, “procedure”, “product”, “regimen”, “substance”, “technique”; technical terms (eg “vector”, “virus”, “modified cells”, “Ad-p53”); tradenames (eg “TRICOM”, “TNFerade”), “treated cells” | | |
| | | | |
| −1 | Any of the above when preceded by adjectives “experimental”, “investigational”, “research”, “study”, “test” (eg “study drug”, “experimental gene therapy”, etc) | | |